We rank companies based on fund manager, research analyst and news sentiment
APLS stock icon

Apellis Pharmaceuticals
APLS

$47.53
0.04%
 

About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Employees: 702

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 28 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

178% more call options, than puts

Call options by funds: $268M | Put options by funds: $96.4M

66% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 38

59% more capital invested

Capital invested by funds: $4.3B [Q3] → $6.81B (+$2.52B) [Q4]

10% more funds holding

Funds holding: 251 [Q3] → 276 (+25) [Q4]

0.17% more ownership

Funds ownership: 95.82% [Q3] → 95.99% (+0.17%) [Q4]

10% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 9 (-1) [Q4]

26% less repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 106

Research analyst outlook

28 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$42
12%
downside
Avg. target
$75
58%
upside
High target
$106
123%
upside

28 analyst ratings

21 positive
75%
neutral
25%
negative
0%
Wedbush
Laura Chico
20%upside
$57
Neutral
Maintained
17 Apr 2024
HC Wainwright & Co.
Douglas Tsao
94%upside
$92
Buy
Reiterated
15 Apr 2024
Needham
Joseph Stringer
79%upside
$85
Buy
Reiterated
9 Apr 2024
Mizuho
Graig Suvannavejh
26%upside
$60
Neutral
Maintained
27 Mar 2024
JP Morgan
Anupam Rama
66%upside
$79
Overweight
Maintained
6 Mar 2024

Financial journalist opinion